RXRX Overview

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Wall Street analysts forecast RXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXRX is7.75 USD with a low forecast of 5.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Recursion Pharmaceuticals Inc revenue for the last quarter amounts to 5.00M USD, decreased -80.16 % YoY.

Recursion Pharmaceuticals Inc. EPS for the last quarter amounts to -0.36 USD, increased 5.88 % YoY.

Recursion Pharmaceuticals Inc (RXRX) has 840 emplpoyees as of January 30 2026.

Today RXRX has the market capitalization of 2.00B USD.